Business Continuity Plan – COVID-19

Banner Business Continuity Plan – Covid-19

In the current context of the COVID-19 Coronavirus pandemic, we wanted to inform you of the measures taken by the company to ensure the continuity of its business.

Oncodesign activated its "Pandemic Crisis Management Plan" on March 12, 2020 which covers the whole company, our laboratories, quality services, IT infrastructure, human resources and logistics in order to guarantee the implementation of our services, in compliance with any additional instructions that the health authorities may decide.

Preventive measures have already been implemented to protect our employees and to adapt work organization.

I read the measures 

[Congress] 14th WRIB – !NEW DATES! 22 – 26 June – Phoenix Arizona – USA

Banner [Congress] 14th WRIB – NEW DATES 22 – 26 June –  Phoenix Arizona – USA

LAST MINUTE INFORMATION: Given the rapidly evolving COVID-19 coronavirus outbreak, the 14th WRIB have been POSTPONED at the 22-26 June.

Our teams remains available for any of your projects. Don't hesitate to contact us!

I fix a meeting! 

Customized bioanalytical services with regulatory expertise

Our scientists have developed and validated more than 50 assays (chemical and biological entities) in liquid or tissue matrices as part of preclinical and clinical projects.

Our experience and our highly qualified teams will advise you on the assay method to be implemented according to your molecule and in compliance with good laboratory practices and international standards.

We are at your disposal and at your side to identify, optimize and measure your molecules.

[Press release] Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease

17/02/20

DOWNLOAD

[Congress] EMIM !NEW DATES! 25-28 August 2020 – Thessaloniki – Greece

[Congress] EMIM  NEW DATES 25-28 August 2020 – Thessaloniki –  Greece

LAST MINUTE INFORMATION: Given the rapidly evolving COVID-19 coronavirus outbreak, the 15th European Molecular Imaging Meeting have been POSTPONED at the 25-28 August.

Our teams remains available for any of your projects. Don't hesitate to contact us!

I fix a meeting

Meet Cyril Berthet, Pharmaco-imaging Unit Director, at EMIM!

It takes 2 to tango: compound labeling and complementary imaging approaches to show how your compound works & targets the right patient.  

Through pharmaco-imaging, the results of preclinical studies can influence the early decision to continue or interrupt the development of a drug candidate. In the clinical development phase, imaging offers an exceptional opportunity to follow the drug in humans with the same techniques developed during the preclinical phase. Novel therapies are converging towards precision medicine, for which pharmaco-imaging is indispensable to all players in the drug development cycle – from the pharmaceutical industry to clinicians – to ensure that the most appropriate treatments are being matched to the needs of the patient.

Explore our multi-modal pharmaco-imaging & targeted radiotherapy expertise for your preclinical projects:

  • Design & implementation of the radionuclide labeling of your chemical or biological molecules of interest
  • Biodistribution of therapeutic drugs using non-invasive techniques
  • Development of translational nuclear medicine biomarkers
  • Evaluation of targeted radiotherapy efficacy